Bonum Therapeutics to Present Poster on Lead Program at AACR 2024

Presentation will highlight publicly for the first time preclinical data on Bonum’s lead cLAG3-IL2 program, demonstrating the power of its conditionally active platform.

SEATTLE--(BUSINESS WIRE)--Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic. Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA.

Presentation details are as follows:

Abstract Title: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells.”

Presenter: Justin Killebrew, PhD, Senior Director, Immuno-Oncology Discovery at Bonum Therapeutics

Abstract Number: 4062

Date/Time: Tuesday, April 9, 2024, 9:00 AM - 12:30 PM PT

Session Title: Immune Modulation with Cytokines

The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3⁺ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic.

John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.”

The poster will be available on the Bonum website on the day of the presentation.

Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022.

Bonum’s core platform enables the engineering and development of a broad array of important medicines. Initially, Bonum is applying the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, it is seeking partners for applications of its technology in other disease areas where the partner brings expertise in a specific biology and can help guide choices to create new therapies and reach patients as quickly as possible.

About Bonum Therapeutics

Bonum Therapeutics is a privately held biotechnology company focused on the generation of a new class of therapeutics based on a proven technology platform that utilizes principles of allosteric regulation to create highly active and less toxic medicines. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus significant milestones. Using a novel approach, Bonum’s molecules combine a sensor component directed against a specific biological marker and a therapeutic component. When the sensor binds its target, the molecule reversibly changes shape and becomes active, delivering potent activity only where it is needed. The technology is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. Bonum’s initial efforts are focusing on regulated immunocytokines, including conditionally active IFN-alpha, IL-12, and TGF-beta, while it pursues additional applications in partnership with others.

The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at www.BonumTx.com and connect with us on LinkedIn and X (Twitter).